$AADI
Aadi Bioscience, Inc.

2019 Q4 Form 10-K Financial Statement

#000156459020011174 Filed on March 16, 2020

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q3 2019 Q2
Revenue $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.540M $2.160M $2.800M
YoY Change -57.46% -34.15% -10.83%
% of Gross Profit
Research & Development $2.130M $2.845M $2.264M
YoY Change -59.43% -34.55% -46.46%
% of Gross Profit
Depreciation & Amortization $30.00K $20.00K $20.00K
YoY Change 200.0% 0.0% 100.0%
% of Gross Profit
Operating Expenses $4.657M $4.967M $5.979M
YoY Change -47.48% -34.85% -18.87%
Operating Profit -$4.657M -$4.967M -$5.979M
YoY Change -47.47% -144.35% -0.95%
Interest Expense $170.0K $239.4K $290.4K
YoY Change -51.43% -28.12% 524.95%
% of Operating Profit
Other Income/Expense, Net $211.1K $318.7K $295.3K
YoY Change -39.27% -6.11% 535.55%
Pretax Income -$4.450M -$4.650M -$5.680M
YoY Change -47.77% -140.29% -5.18%
Income Tax
% Of Pretax Income
Net Earnings -$4.450M -$4.648M -$5.684M
YoY Change -47.77% -140.29% -5.11%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.64 -$1.72 -$2.10
COMMON SHARES
Basic Shares Outstanding 40.59M 40.59M
Diluted Shares Outstanding 40.59M

Balance Sheet

Concept 2019 Q4 2019 Q3 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $38.50M $43.40M $48.20M
YoY Change -38.5% -36.92% -29.94%
Cash & Equivalents $38.52M $43.39M $48.16M
Short-Term Investments
Other Short-Term Assets $734.8K $876.5K $264.3K
YoY Change 19.35% -26.96% 23.82%
Inventory
Prepaid Expenses $311.2K $538.3K $368.0K
Receivables
Other Receivables
Total Short-Term Assets $39.57M $44.80M $48.79M
YoY Change -38.16% -35.99% -29.72%
LONG-TERM ASSETS
Property, Plant & Equipment $164.2K $281.7K $297.6K
YoY Change 66.77% 181.71% 223.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00 $0.00
YoY Change
Total Long-Term Assets $366.3K $747.4K $810.7K
YoY Change 162.76% 273.71% 617.34%
TOTAL ASSETS
Total Short-Term Assets $39.57M $44.80M $48.79M
Total Long-Term Assets $366.3K $747.4K $810.7K
Total Assets $39.94M $45.55M $49.60M
YoY Change -37.72% -35.11% -28.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $439.8K $751.0K $511.2K
YoY Change -26.17% 4.74% -52.38%
Accrued Expenses $2.900M $2.900M $3.100M
YoY Change -40.82% 0.0% 63.16%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.334M $3.601M $3.596M
YoY Change -38.9% -1.19% -83.38%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $100.0K $200.0K $300.0K
YoY Change
Total Long-Term Liabilities $100.0K $200.0K $300.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.334M $3.601M $3.596M
Total Long-Term Liabilities $100.0K $200.0K $300.0K
Total Liabilities $3.401M $3.837M $3.884M
YoY Change -37.67% 6.59% -82.02%
SHAREHOLDERS EQUITY
Retained Earnings -$142.2M -$137.8M -$133.1M
YoY Change 19.57% 24.76% 9.15%
Common Stock $178.8M $179.5M $178.9M
YoY Change 0.64% 1.44% 5.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$9.093M $41.71M $45.72M
YoY Change
Total Liabilities & Shareholders Equity $39.94M $45.55M $49.60M
YoY Change -37.72% -35.08% -28.67%

Cashflow Statement

Concept 2019 Q4 2019 Q3 2019 Q2
OPERATING ACTIVITIES
Net Income -$4.450M -$4.648M -$5.684M
YoY Change -47.77% -140.29% -5.11%
Depreciation, Depletion And Amortization $30.00K $20.00K $20.00K
YoY Change 200.0% 0.0% 100.0%
Cash From Operating Activities -$4.860M -$4.770M -$5.140M
YoY Change -21.49% -23.31% -139.21%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $10.00K $120.0K
YoY Change -100.0% -50.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$10.00K -$120.0K
YoY Change -100.0% -50.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 0.000
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -4.860M -4.770M -5.140M
Cash From Investing Activities 0.000 -10.00K -120.0K
Cash From Financing Activities 0.000 0.000 0.000
Net Change In Cash -4.860M -4.780M -5.260M
YoY Change -21.61% -16033.33% -109.56%
FREE CASH FLOW
Cash From Operating Activities -$4.860M -$4.770M -$5.140M
Capital Expenditures $0.00 $10.00K $120.0K
Free Cash Flow -$4.860M -$4.780M -$5.260M
YoY Change -21.61% -23.4% -140.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38524536
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
311154
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
734785
CY2019Q4 us-gaap Assets Current
AssetsCurrent
39570475
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
164187
CY2018 us-gaap Operating Expenses
OperatingExpenses
31338674
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-24444082
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-11181244
CY2019Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
40000
CY2019Q4 us-gaap Assets
Assets
39936786
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3231450
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
102555
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5456917
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9756185
CY2019 us-gaap Restructuring Costs
RestructuringCosts
1863495
CY2019 us-gaap Operating Expenses
OperatingExpenses
24444082
CY2019 arpo Grant Income
GrantIncome
142729
CY2018 arpo Grant Income
GrantIncome
6394
CY2019 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1030839
CY2018 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
778215
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1173568
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
784609
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-23270514
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-10396635
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40588004
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33930846
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
17435489
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
48119027
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
76832
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3431862
CY2019 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
53440
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1085842
CY2018 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
3502543
CY2019 us-gaap Depreciation
Depreciation
76501
CY2018 us-gaap Depreciation
Depreciation
46686
CY2019 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-94713
CY2019 arpo Consulting Expenses Related To Warrants
ConsultingExpensesRelatedToWarrants
53440
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
1085842
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
3431862
CY2019 arpo Increase Decrease In Prepaid Research And Development Contracts
IncreaseDecreaseInPrepaidResearchAndDevelopmentContracts
-443238
CY2018 arpo Increase Decrease In Prepaid Research And Development Contracts
IncreaseDecreaseInPrepaidResearchAndDevelopmentContracts
441252
CY2019 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
119104
CY2018 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
293460
CY2019 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-960
CY2018 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
20000
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2217598
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1864753
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23852522
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5808046
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
236952
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
37912
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-236952
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-37912
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
76832
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
51621570
CY2018 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3502543
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
48195859
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-24089474
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
42349901
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
62614010
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20264109
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
38524536
CY2018 arpo Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
P3Y
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: prepaid and accrued research and development expense, stock-based compensation expense, revenue recognition and income taxes. </p>
CY2018Q4 arpo Accrued Project Costs Current
AccruedProjectCostsCurrent
2232014
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
13463
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
173182
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
493037
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
409580
CY2019 us-gaap Intangible Assets Finite Lived Policy Costs Incurred To Renew Or Extend
IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Patents </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs incurred in connection with the application for and issuances of patents are expensed as incurred. </p>
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Off-Balance Sheet Risk </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents are the only financial instruments that potentially subject the Company to concentrations of credit risk. At December&#160;31, 2019 and 2018, the Company maintains its cash and cash equivalents with high-quality, accredited financial institutions and, accordingly, such funds are subject to minimal credit risk. The Company has no significant off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements. </p>
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4666728
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
2682010
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5335850
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2395265
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2940585
CY2019Q4 arpo Warrants Vesting Period
WarrantsVestingPeriod
P6M
CY2019 arpo Class Of Warrant Or Right Expiration Date
ClassOfWarrantOrRightExpirationDate
2024-10-24
CY2018 arpo Class Of Warrant Or Right Expiration Date
ClassOfWarrantOrRightExpirationDate
2020-03-15
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.72
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.64
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.47
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.23
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.73
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4.17
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.90
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.85
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
2.70
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
328850
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
311131
CY2019Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
600000
CY2018Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
317562
CY2019Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
317562
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.486
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
5.00
CY2018Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2019Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
793913
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
487923
CY2018Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1877455
CY2019Q4 arpo Accrued Retention Bonus Current
AccruedRetentionBonusCurrent
521859
CY2019Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
43470
CY2018Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
90663
CY2019Q4 arpo Accrued Project Costs Current
AccruedProjectCostsCurrent
382131
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.60
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.93
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.15
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M26D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M26D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y2M8D
CY2018 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P6Y4M13D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y2M23D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y
CY2019 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P3Y11M23D
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2738704
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
142788
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
142788
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
139108
CY2019Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2309337
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.11
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
2.22
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y4M9D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y25D
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0224
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0285
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6488
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6599
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0415
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.0637
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.0056
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.2465
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
24966019
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
413048
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
738768
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
4640960
CY2019Q4 arpo Deferred Tax Asset Operating Lease Right Of Use Assets Net
DeferredTaxAssetOperatingLeaseRightOfUseAssetsNet
37793
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2423
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
13276
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
30799011
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
25010730
CY2019Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
24967
CY2018Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
8390
CY2019Q4 arpo Deferred Tax Liabilities Operating Lease Liability
DeferredTaxLiabilitiesOperatingLeaseLiability
36044
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
61011
CY2018Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
8390
CY2019Q4 arpo Deferred Tax Assets And Liabilities Net Before Valuation Allowance
DeferredTaxAssetsAndLiabilitiesNetBeforeValuationAllowance
30738000
CY2018Q4 arpo Deferred Tax Assets And Liabilities Net Before Valuation Allowance
DeferredTaxAssetsAndLiabilitiesNetBeforeValuationAllowance
25002340
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
30738000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
25002340
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
5735658
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2832878
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2018Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23270514
CY2018 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10396635
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
8841293
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
5978919
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
4966638
CY2019Q4 us-gaap Operating Expenses
OperatingExpenses
4657232
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8841293
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5978919
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4966638
CY2019Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-4657232
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
348468
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
295303
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
318708
CY2019Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
211089
CY2019Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4446143
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2018Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27045509
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.28
CY2018Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27045509
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40588004
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40588004
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40588004
CY2019Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40588004
CY2018Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27340914
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40527722
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1333333
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18821953
CY2018Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2144
CY2018Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
arpo:LicenseRevenueAndOtherMember
CY2018Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
arpo:LicenseRevenueAndOtherMember
CY2018Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
arpo:LicenseRevenueAndOtherMember
CY2018Q4 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
arpo:LicenseRevenueAndOtherMember
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
7476648
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
7369788
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
7623916
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7476648
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6036455
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
11198037
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
51116
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
46464
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
339441
CY2018Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7425532
CY2018Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5989991
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
11537478
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2018Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27340914
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40961620
CY2019Q4 arpo Penalties On Termination Of Lease
PenaltiesOnTerminationOfLease
0
CY2019Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
242690
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
242581
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y6M29D
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1328
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
117781
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
69685
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
187466
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
17473
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
169993
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2018 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2019Q4 us-gaap Defined Contribution Plan Sponsor Location Extensible List
DefinedContributionPlanSponsorLocationExtensibleList
country:US
CY2018Q4 us-gaap Defined Contribution Plan Sponsor Location Extensible List
DefinedContributionPlanSponsorLocationExtensibleList
country:US
CY2019Q4 us-gaap Defined Contribution Plan Tax Status Extensible List
DefinedContributionPlanTaxStatusExtensibleList
us-gaap:QualifiedPlanMember
CY2018Q4 us-gaap Defined Contribution Plan Tax Status Extensible List
DefinedContributionPlanTaxStatusExtensibleList
us-gaap:QualifiedPlanMember
CY2018Q2 us-gaap Proceeds From License Fees Received
ProceedsFromLicenseFeesReceived
20000000

Files In Submission

Name View Source Status
0001564590-20-011174-index-headers.html Edgar Link pending
0001564590-20-011174-index.html Edgar Link pending
0001564590-20-011174.txt Edgar Link pending
0001564590-20-011174-xbrl.zip Edgar Link pending
arpo-10k_20191231.htm Edgar Link pending
arpo-20191231.xml Edgar Link completed
arpo-20191231.xsd Edgar Link pending
arpo-20191231_cal.xml Edgar Link unprocessable
arpo-20191231_def.xml Edgar Link unprocessable
arpo-20191231_lab.xml Edgar Link unprocessable
arpo-20191231_pre.xml Edgar Link unprocessable
arpo-ex231_10.htm Edgar Link pending
arpo-ex311_6.htm Edgar Link pending
arpo-ex312_8.htm Edgar Link pending
arpo-ex321_7.htm Edgar Link pending
arpo-ex322_9.htm Edgar Link pending
arpo-ex43_247.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gzt2txml0dak000001.jpg Edgar Link pending
gzt2txml0dak000002.jpg Edgar Link pending
gzt2txml0dak000003.jpg Edgar Link pending
gzt2txml0dak000004.jpg Edgar Link pending
gzt2txml0dak000005.jpg Edgar Link pending
gzt2txml0dak000006.jpg Edgar Link pending
gzt2txml0dak000007.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending